Introduction
Adeno-associated viruses (AAV) are parvoviruses that have not been associated with any disease in humans. 1 Given their safety and low toxicity, ability to infect nondividing cells and long-term gene expression when used as a vector for gene delivery, AAV has become a favored candidate for gene therapy. 2, 3 Several clinical trials utilizing AAV for the treatment of cystic fibrosis, hemophilia, prostate cancer and muscular dystrophy are underway, with early evidence of human clotting factor IX production in hemophilia B patients. [4] [5] [6] In spite of its acknowledged safety, AAV has recently produced surprises in the field of gene therapy. Traces of AAV have been observed in treated patient's semen, and liver tumors of uncertain cause have been found in diseased mice treated with AAV vectors. 7 Concerns surrounding the latter findings have been allayed, in part, by attribution of the abnormal pathology to the long-term survival of a mouse model normally subject to early mortality in the absence of AAV-mediated therapeutic gene delivery. 8 Immune responses against AAV, although mild and noninflammatory, have been documented. Of the known AAV serotypes, antibodies against serotype 2 appear at the highest frequencies (ie, 30-90% of human populations), while those against serotypes 1 and 5 are observed less often. [9] [10] [11] [12] [13] Furthermore, immunities to AAV capsids and/or transgene products represent a considerable barrier to efficient gene delivery by AAV and repeated administrations. 11, [14] [15] [16] [17] [18] Species and strains of animals, 14, 19, 20 routes of administration 16, 17, 21 and cellular localization of transgene products 22 are among the most important factors that influence the anti-AAV immunity and the subsequent outcome of AAV-mediated gene therapy. However, most studies have used a limited number of mouse strains and assessed the immune responses in a narrow fashion. Therefore, the impact of genetic background on the immunological safety of AAV gene delivery remains largely unknown. We recently observed muscle inflammation in nonobese diabetic (NOD) mice, a model for autoimmune type I diabetes, that had received interleukin-4 (IL-4) and interleukin-10 (IL-10) therapy via intramuscular AAV2-IL-4 or AAV2-IL-10 injections. 23 This further raised the question as to how genetic predisposition to autoimmunity affects the effectiveness of AAV gene therapy.
The objective of this study was to evaluate the effect of genetic background, particularly that of predisposition to autoimmunity, on the humoral and cellular immune response against AAV2 and AAV2-delivered transgene products, as well as its impact on the efficiency of repeated AAV gene therapy.
Results
To investigate the influence of genetic background on immune responses to AAV2 virions and AAV2 transgene products, we selected 12 mouse strains (Table 1) . These choices were based on popularity in scientific use and genetic predisposition to autoimmunity. In particular, models for type I diabetes (NOD), systemic lupus erythematosus (NZB/NZW F1 hybrid), lymphoproliferative disease (MRL-lpr) and immunodeficiency (NOD.scid) were included.
Humoral immune responses to AAV2 virions in mice
As AAV2 has thus far been the most commonly used in experimental studies and human clinical trials, we developed a recombinant AAV2 vector encoding GFP (AAV2-GFP). Humoral immunity to the AAV2 capsids and GFP was investigated following a single intramuscular administration of AAV2-GFP. A broad range of serum dilutions (1:10-1:4 Â 10 6 ) were analyzed in assessments of anti-AAV capsid antibody levels.
As expected, all immunocompetent mice administered AAV2 developed antibodies to the virus, while immunodeficient NOD.scid mice and animals treated with saline did not develop immune responses to AAV2. However, surprisingly, a previously unreported prozone effect in the antibody response was observed in these strains except MRL-lpr ( Figure 1a) . For most strains, the linear range of anti-AAV antibody detection appeared to be between 1:10 4 and 1:10 5 serum dilutions. An unexpected drop in the level of anti-AAV2 antibodies occurred at the high end of the dose-response curve, commonly referred to as prozone effect. 24 Therefore, standard laboratory dilutions, which usually range from 1:10 to 1:2000 as used in previous studies, [15] [16] [17] would result in a considerable underestimation of anti-AAV2 antibody concentrations in mice. The specificity of ELISA for anti-AAV2 antibodies was confirmed by a competition assay (Figure 1b ). An excess of free AAV2 capsids completely abrogated the binding of NOD mouse serum. However, a partial competition was observed in MRL-lpr mouse serum, a finding most likely related to the strain's development of hypergammaglobulinemia and high quantity production of antibodies with low specificity. 25 The antibody response to AAV2 capsids was examined for 6 weeks following an intramuscular injection of AAV2-GFP. The anti-AAV2 antibodies in most immunocompetent strains peaked at 4 weeks and declined by 6 weeks postinjection (Figure 1c) . Extremely high levels of antibodies were observed in C57BL/6, NOD, NOD.IL10
À/À (IL-10 knockout mice on NOD background) and NOR mice, which amounted to 2000-4000 mg/ml (quantity extrapolated from the standard curve using A20 antibody). This result is in accordance with the concept that the prozone effect usually occurs with high-titer antibodies in response to viral infection. 26 Isotyping of anti-AAV2 antibodies revealed IgG and IgM, but no IgE or IgA isotypes (Figure 1d ). In NOD mice, IgG persisted for at least 6 weeks while IgM appeared only at 2 weeks, a finding consistent with the role of IgM in primary immune response. In contrast, MRL-lpr showed a constant level of IgG and a transient elevation in IgM, both largely nonspecific to AAV2 capsids as they were present even before treatment. Neutralizing antibodies to AAV2 capsids were detected in all immunocompetent strains (Figure 1e ). The highest levels were observed in CB10-H2b, NOD, NOD IL10 
Humoral immune responses to GFP in mice
There was efficient expression of GFP in muscles of all strains, as illustrated in Figure 2a -c. However, antibody responses to GFP were only observed in NOD, NOD In addition to indicating the model (or common usage in studies) for each strain, notation is given to the major histocompatibility (MHC) class I and class II usage; given the major role for such molecules in regulating immune responsiveness.
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, NOR, NZW, MRL and MRL-lpr mice, all of them prone or predisposed to autoimmunity. The antibody levels remained high throughout the time of investigation. Strains without immunological abnormalities or alterations and most common in previous investigations of AAV gene therapy, such as BALB/c, C57BL/6 and C3H, failed to develop antibodies to GFP (Figure 2d ). No prozone effect was observed with anti-GFP antibodies (data not shown). Competition assays confirmed the specificity of ELISA in NOD and other strains, whereas MRL-lpr mice demonstrated large amounts of antibodies with low specificity (Figure 2e ). Anti-GFP antibody isotypes involved mainly IgG in NOD mice, with negligible IgM, IgE or IgA (Figure 2f ).
Effect of immune status on repeated administration of AAV2
To investigate the effect of immune status on the efficacy of gene delivery involving repeated administration of AAV serotype 2, three mouse strains, C57BL/6, NOD and NOD.scid, were treated with two sequential injections. These three strains were selected to represent different immune status: C57BL/6 (normal immunocompetent), NOD (autoimmune) and NOD.scid (immunodeficient). Animals received either saline or AAV2-GFP for the first treatment, followed 4 weeks later by a second injection of AAV2 vector expressing human a1-antitrypsin (AAV2-a1-AT). In accordance with the findings in Figure 1 , both C57BL/6 and NOD mice, but not Impact of genetic background on AAV2 immunity YC Zhang et al NOD.scid mice, developed anti-AAV2 neutralizing antibodies. However, NOD mice displayed a stronger and elevated secondary response to AAV2 upon the repeated antigenic exposure (Figure 3a) . Again, anti-GFP antibodies were observed only in NOD strain, which culminated at 4 weeks after the second injection and declined afterwards (Figure 3b) . In C57BL/6 and NOD mice, only animals that received saline for the first treatment produced detectable levels of human a1-AT in serum following the AAV2-a1-AT treatment. However, in the NOD.scid strain, comparable human a1-AT concentrations were observed in all animals regardless of the first injection (Figure 3c ), findings in accordance with the previous reports.
14-18 Anti-a1-AT antibodies were found only in NOD mice that expressed a1-AT, but not in any C57BL/6 or NOD.scid mice (Figure 3d ). This further emphasizes that genetic predisposition to autoimmunity specifically imparts immune responsiveness to AAV2-delivered transgene products.
To evaluate the effects of autoimmunity on AAV2-mediated delivery of self-proteins (unlike foreign proteins such as GFP and human a1-AT), we treated C57BL/ 6, NOD and NOD.scid mice with an AAV2 vector expressing murine IL-10, a cytokine that has shown therapeutic value in preventing type I diabetes in NOD mice. Three out of six NOD mice, and absolutely no C57BL/6 or NOD.scid mice, produced antibodies to murine IL-10 following AAV2-IL10 gene therapy (data not shown). This specific immune reaction in NOD mice might exert detrimental effects on transgene expression, as AAV2-IL-10 delivered by intramuscular injection produced a persistent release of IL-10 into the circulation in both NOD.scid and C57BL/6 mice, in contrast to the transient IL-10 production in NOD mice. A second injection given at 10 weeks after the first injection failed to restore or increase IL-10 expression in NOD and C57BL/6 mice owing to the generation of neutralizing antibodies to AAV2, while in NOD.scid mice the repeated administration further elevated the systemic level of IL-10 ( Figure 3e ).
Histology and cell-mediated immunity
Although humoral responses were elicited against AAV2 capsids in most mice and against transgene products including GFP and human a1-AT in specific autoimmune strains, histopathological analysis revealed no inflammation at the site of intramuscular injection. Other organs including heart, lung, liver, spleen, kidney, brain, skin, ovary, lymph nodes and salivary glands showed no abnormal histological findings (data not shown). Additional studies on antigen-stimulated responses in the splenocytes isolated from AAV2-GFP-treated mice showed, with one exception (NOD.IL10
À/À responses to high-dose GFP), no significant changes in the proliferation rate (Table 2) 
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Discussion
In the face of increased awareness and concern for safety and reliability of gene delivery vectors, AAV has become a preferred candidate for human gene therapy. 3 Numerous studies have demonstrated promise for AAV as a safe and efficient vector in preclinical and clinical trials. [4] [5] [6] However, there have not been any significant efforts dedicated to understanding the impact of strain background and predisposition to autoimmunity on AAVmediated gene transfer. In the current study, we investigated the immune responses against AAV2 capsids and transgene products following intramuscular delivery of AAV2 vectors. Our results suggest that levels of anti-AAV immunity may have, historically, been subject to underestimation due to inadequate dilution of serologic samples.
The underestimation of anti-AAV2 antibodies in previous reports most likely resulted from unawareness of the prozone effect observed in our study. In terms of why this developed, the prozone effect in mice might be a consequence of the high vector doses (2.6 Â 10 11 viral particles) used. Many studies have suggested that a certain dose threshold of AAV2 has to be reached in order to produce therapeutic levels of useful proteins. 30, 31 This raises a possibility of strong anti-AAV2 immunity in humans receiving therapeutic doses of AAV2 vectors. On the other hand, it is also noteworthy that the prozone effect was not detected in our studies of neutralizing antibodies. Thus, strong humoral responses (total antibodies) to AAV2 may not necessarily predict the in vivo performance of AAV2 vectors as well as the efficacy of readministration.
This study also clearly demonstrated the role of genetic predisposition in the genesis of a humoral immune response to viral gene therapy. Published studies in mice document strain-related differences in nonviral gene delivery, 32 and in antibody responses to DNA and peptide immunization. 33, 34 Although all immunocompetent mouse strains tested in the present study developed antibodies to AAV2, only genetic predisposition to autoimmune diseases specifically conferred immune responsiveness to AAV2-delivered Impact of genetic background on AAV2 immunity YC Zhang et al transgene products, whether in the form of intracellular proteins (eg, GFP) or secreted proteins (eg, murine IL-10 and human a1-AT). This immune response could be functionally deleterious which might lead to transient transgene expression. We would predict that transient expression is most likely to occur with secreted and membrane proteins but not intracellular proteins, as intracellular proteins would be shielded from circulating antibodies against them.
In the context of existing knowledge on AAV2 immunity, our findings may appear conflicting at the first glimpse, as antibodies against AAV2-delivered transgenes (eg human factor IX, 17, 35 ovalbumin, 21 b-Gal 36,37 ) have been found in normal immunocompetent mice by multiple independent investigators. However, in a majority of such literature, AAV2-delivered transgenes that have been reported tobe capable of inducing immune responses that are either pathogen-specific antigens when AAV2 vectors were specifically designed as vaccine, [38] [39] [40] or highly pathogenic in nature (eg ovalbumin, b-Gal). In contrast, the transgenes used in our study (eg GFP) have not been shown to elicit antibody responses when delivered by AAV into immunocompetent animals. 19, 41 Therefore, the humoral responses against these transgenes observed in our study could be attributed to strain differences and, specifically, to autoimmune background. These results suggest that while AAV induces negligible to mild immune response to its transgene products in normal animals (especially in side-by-side comparison to adenovirus), [27] [28] [29] 41 genetic predisposition to autoimmunity is likely able to magnify this response to a significant extent that may render itself functionally deleterious, leading to transient transgene expression.
In the light of these findings, one might question why previous data including long-term preclinical studies and clinical trials with AAV2 have demonstrated the absence of clinically relevant immunization in dogs, nonhuman primates and, most importantly, in humans? While unable to fully answer this question, we can offer some explanations that may explain in part why such findings have not previously been noted. As suggested by our study, immune responsiveness to the AAV2-delivered transgenes in mice is imparted by predisposition to autoimmunity. However, dogs and non-human primates do not normally provide established models of autoimmunity, and most human trials with AAV so far have not focused on autoimmunity.
Among the unexplained or difficult-to-interpret observations of this study were the findings that NZB/ NZW F1 mice did not produce antibodies against GFP. In addition, the titer of antibody generated was much lower in other strains of mice that were not associated with NOD. These differences implicate that the generation of antibodies against the transgene is not only associated with autoimmunity, but may also be associated with other genetic background including MHC type. On that point, we must make clear that the principal goal of this study (nor was one of the tested outcomes) did not involve MHC mapping for immune responsiveness. Indeed, as previously indicated, the rationale underlying the selection of the 12 strains was that of being prone to autoimmunity and commonality to laboratory research. Any future attempts to map potential MHC associations would clearly involve investigations of different groups of animals with a far more diverse array of MHC backgrounds as well as a more focused evaluation of MHC class I versus class II and I-A versus I-E.
Our observation of autoantibodies against murine IL-10 in some NOD mice, but not in other nonautoimmune mice, suggests that gene therapy may break tolerance to a self-antigen in an autoimmune environment. This implication is potentially very important to human gene therapy. However, further studies evaluating self-antigens that do not contain endogenous immune inhibiting activity as IL-10 in a broader selection of animal models for autoimmunity are required to test this possibility. It is also noteworthy that 50% (three out of six) but not all NOD mice developed detectable amounts of anti-IL10 antibodies, suggesting that other factors such as the severity of autoimmune status in individual animals may influence the production of autoantibodies. In addition, there appears to be a time window for immune tolerance to develop in autoimmune animals, as transient IL-10 production up to 14 weeks in NOD mice afforded by a single intramuscular administration of AAV2-IL10 vector conferred a complete prevention of type I diabetes. 23 This observation of disease prevention, 23 as well as our findings in the current report of attenuated transgene production over time, would appear to be at conflict. Specifically, how can disease be modified in studies of NOD mice, 23, 31 if the transgene production was nullified? We believe the answer is that the window of transgene production, although eventually diminished, is adequate and sufficient in terms of the duration needed to provide for long-term disease prevention. This issue, as well as the potential influence that gender, age, route of administration and vector dose have on eliciting these immunities, will require further investigation. Indeed, human autoimmune disorders are associated with many unique differences in gender and age at onset. Further, the route of administration and vector dose have been shown to be factors of influence in terms of immune responsiveness.
In summary, future studies utilizing AAV vectors should take into account the potential for host background, specifically pre-existing autoimmunity or susceptibility to autoimmune diseases, which may limit the therapeutic effectiveness of AAV-delivered transgenes. Patients with autoimmune disorders such as type I diabetes, lupus and rheumatoid arthritis may not respond to AAV2-based gene therapy as well as other patients, and efficient immunosuppression may be required during the treatment to circumvent the host's immune responses to therapeutic genes. 14, 35 We also need to emphasize that the observations reported here are limited to intramuscular delivery of AAV2 vectors. The humoral and cellular immunity associated with other routes of administration and different AAV serotypes remains to be evaluated by further investigations.
Materials and methods
Mice
All animal procedures performed were reviewed and approved by the University of Florida Animal Care and Use Committee. All animals were female and obtained from The Jackson Laboratory (Bar Harbor, ME, USA).
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A fused CMV-chicken b-actin (CB) promoter was used to drive the expression of GFP, human a1-antitrypsin and murine IL-10 in recombinant AAV2 vectors. These vectors were produced and purified at the Powell Gene Therapy Center, University of Florida, as previously described 42, 43 Briefly, HEK 293 cells were cotransfected by the rAVV plasmid and the helper plasmid pDG for 48-60 h. Cells were harvested, and the crude lysate was purified through an iodixanol step gradient followed by heparin affinity chromatography. The titers for the physical and infectious AAV2 particles were determined by dot blot and infectious center assay, respectively. The vectors were 99% pure as illustrated by silver-stained SDS-PAGE. AAV2 vectors were injected intramuscularly into the caudal muscle of the pelvic limb of mice. The dosages used were 1.4 Â 10 9 infectious particles (equivalent to 2.6 Â 10 11 physical particles) of AAV2-GFP, 1.0 Â 10 9 infectious particles (equivalent to 1.6 Â 10 11 physical particles) of AAV2-a1-AT and 2.0 Â 10 9 infectious particles (equivalent to 7.3 Â 10 11 physical particles) of AAV2-IL10, per animal.
ELISA for anti-AAV2 antibodies
ELISA plates were coated with 10 10 particles of AAV2 capsids per well at 41C overnight; blocked at 371C for 2 h; incubated with serially diluted A20 monoclonal antibody (Progen) or mouse sera at 41C overnight; incubated with HRP-conjugated anti-mouse Ig, then with TMB substrate and H 2 O 2 ; reaction stopped by H 3 PO 4 ; and read at 450 nm. The titer of anti-AAV2 antibodies was calculated based on the standard curve of A20 antibody.
Neutralizing antibodies to AAV serotype 2 capsids
HEK 293 cells on 96-well plates were infected with AAV2-GFP that had been incubated with mouse sera and a known negative control serum at the serial dilutions of 50, 200, 800, 3200, 12 800 and 51 200. At 2 days posttransduction, green fluorescence intensity was read and computerized by a fluoroimager. The titer of neutralizing antibodies was defined as the highest dilution that produced 50% fluorescence in comparison to that with negative control serum.
ELISA for anti-GFP antibodies
ELISA was performed similar to assay for anti-AAV antibodies, except that plates were coated with 0.5 mg/ml recombinant GFP, and anti-GFP monoclonal antibody (Clontech) was used as standard.
Antigen-stimulated responses of splenocytes to AAV2 capsids and GFP Following isolation and purification from spleens of AAV2-GFP-treated mice, splenocytes were cultured at 1 Â 10 5 cells/well in 200 ml of RPMI 1640 medium (10% fetal bovine serum) in 96-well round-bottom plates. Splenocytes were separated into four groups with triplicate cultures per group: unstimulated (as negative control); stimulated with AAV2-GFP (1 mg/ml); stimulated with recombinant GFP (1 mg/ml); or stimulated with recombinant GFP (10 mg/ml), respectively. After 48 h of incubation, 20 ml of supernatant was collected from each group for cytokine analysis in response to each antigen. Cytokine levels (IL-2, IL-4, IL-10, IFNg, TNFa) were determined by Luminext (Upstate) assay. On the fifth day of incubation, cells were pulsed with 1 mCi of (methyl-3 H)thymidine per well and harvested 24 h later onto glass fiber filters.
3 H-thymidine incorporation was measured as cpm with a b scintillation counter. Splenocyte proliferation in response to each antigen was indicated by stimulation index (SI). SI was defined as (mean of cpm from stimulated cells)/(mean of cpm from unstimulated cells). SI values of greater than 3.0 were considered significant. The viability of each lymphocyte culture was confirmed with mitogen-induced proliferation and cytokine release in response to 1-10 mg/ml concanavalin A.
Histological analysis
Tissues were obtained from 12 organs: brain, duodenum, heart, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, spleen and stomach. Samples were stained for morphology and GFP.
Statistical analysis
The data are presented as the mean7s.e.m. Student's t-tests and ANOVA testing were used for analyses comparing the different groups, with statistical significance considered if Po0.05.
